Login / Signup

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience.

Gülşah Kavrul KayaalpŞengül ÇağlayanFatma Gül DemirkanVafa GuliyevaGülçin Otar YenerKübra OztürkFerhat DemirSemanur OzdelMustafa CakanHafize Emine SönmezBetul SozeriNuray Aktay Ayaz
Published in: Pediatric rheumatology online journal (2023)
Extending treatment intervals with canakinumab in colchicine-resistant familial Mediterranean fever shows promise for favorable outcomes.
Keyphrases
  • early onset
  • young adults
  • type diabetes
  • metabolic syndrome
  • replacement therapy